Clinical Trials Logo

Calcinosis clinical trials

View clinical trials related to Calcinosis.

Filter by:

NCT ID: NCT04066855 Not yet recruiting - Clinical trials for Chronic Kidney Failure

Sclerostin and Vascular Calcification in CKD and Renal Transplant

Start date: December 2019
Phase:
Study type: Observational

the aim of the research is to determine the degree of vascular calcification in chronic kidney disease and post-transplant and whether there is a correlation with the level of serum sclerostin.

NCT ID: NCT03972566 Not yet recruiting - Raynaud Phenomenon Clinical Trials

Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud Phenomenon

Start date: June 20, 2019
Phase:
Study type: Observational

Background CREST is an acronym for the cardinal clinical features of the syndrome (Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia) and part of the heterogeneous group of sclerodermas. Calcinosis is the pathologic calcification of soft tissues. When symptomatic, they can be tender and painful, ulcerate, and drain a white chalky substance. With time, heterotopic bone formation may occur. Inflammatory reactions also intermittently occur at the site of calcinosis. It has been suggested that TGF-beta3 plays a major role in the pathogenesis of calcinosis. A variety of medical therapies have been used to try to alleviate patient symptoms. These include pharmacological approaches (e..g., warfarin), surgical curettage or excision, as well as carbon dioxide laser treatments. No consistently reliable pharmacological treatment seems to be available to prevent or eliminate calcinosis. Curettage and excision and carbon dioxide laser of localized painful large deposits can relieve symptoms but recurrence is common. In addition, aggressive curettage or excision can damage deeper neurovascular structures. While calcinosis is associated with significant morbidity its treatment remains a challenge. Photobiomodulation (PBM) has been shown to promote wound healing, suppress inflammatory reactions and regulate collagen synthesis in a number of in vitro and in vivo studies. Human skin contains photolabile nitric oxide (NO) derivatives which decompose after UVA irradiation and release vasoactive NO. However, aside from blue light, barely nothing has been reported about the effects of red and NIR wavelengths. Method A custom-built air tight sleeve which envelopes the forearm of a subject will be used to measure the NO emanating from the skin under photobiomodulation conditions (red & NIR) and quantified by chemiluminescence detection. Simultaneously, CREST patient's hands exhibiting calcinosis and/or Raynaud phenomenon will be exposed to exogenous gaseous nitric oxide (INOMAX) to determine the vascular impact of this approach. This case series will assess Light Emitting Diode (LED) based PBM therapy as a treatment alternative for cutaneous calcinosis and the effects of gaseous NO on calcinosis and/or Raynaud phenomenon in CREST patients.

NCT ID: NCT03820635 Not yet recruiting - Clinical trials for Diabetic Nephropathies

Markers of Vascular Calcification in Diabetic Nephropathy in Patients With Diabetic Nephropathy

Start date: March 1, 2019
Phase:
Study type: Observational

The study will be conducted at Assiut University Hospital. Eligible subjects will be screened for vascular calcification by Doppler ultrasound examination. A correation between the level of serum Osteopontin (OPN) level and the extent of vascular calcification will be evaluated.

NCT ID: NCT03717389 Not yet recruiting - Clinical trials for Oral Soft Tissue Conditions

The Prevalence of Soft Tissue Calcifications in the Head and Neck Region Using CBCT Among Egyptian Population

Start date: November 2018
Phase:
Study type: Observational

Prevalence of soft tissue calcifications in the head and neck region is not clearly studied in the Egyptian population. Determining the incidence of these calcifications can improve the knowledge of dental practitioners and allow such practitioners to initiate proper diagnostic. And if patients need treatment they can start early by the right therapy to stop the. The aim of this research is to detect and quantify the prevalence of the soft tissue calcifications by cone beam computed tomography (CBCT) images of the head and neck region in the Egyptian population.

NCT ID: NCT03360331 Not yet recruiting - Clinical trials for Vascular Calcification

Effect of Phosphorus on Valvular and Vascular Calcification in ESRD

Start date: December 1, 2017
Phase: N/A
Study type: Observational

Evaluation of the calcifying effect of phosphorus on vascular smooth muscle and detect the association between serum phosphorus and valvular and vascular calcification in end stage renal disease patients

NCT ID: NCT03169400 Not yet recruiting - Oxidative Stress Clinical Trials

Theranova Dialyzer and Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD)

Start date: October 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

The project will be structured in 3 main parts: 1. Effect of sera of ESRD patients on HD using Theranova dialyzer on high-Pi induced vascular calcification in an in vitro model of rat VSMCs. 2. Effect of sera of ESRD patients on HD using Theranova dialyzer on oxidative stress pathways in an in vitro model of rat VSMCs vascular calcification. 3. Study of RNA sequencing, transcriptome analysis gene expression of time course high-P challenged VSMCs studying the effect of sera of ESRD patients on HD using Theranova dialyzer

NCT ID: NCT02418884 Not yet recruiting - Clinical trials for Coronary Artery Disease

The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus

Start date: April 2015
Phase: Phase 4
Study type: Interventional

This study is designed to validate the hypothesis that the treatment of rosuvastatin could increase the score of Calcification of Coronary artery(CAC) density in coronary artery disease(CAD) patients with diabetes mellitus.CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.

NCT ID: NCT02221921 Not yet recruiting - Clinical trials for Aortic Valve Stenosis

Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI

Start date: September 2014
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the safety and effectiveness of the MicroPort's Valve and delivery system for transcatheter aortic valve implantation (TAVI) in severe aortic stenosis who are considered unsuitable for Surgical Valve Replacement.

NCT ID: NCT01458860 Not yet recruiting - Clinical trials for Carotid Artery Stenosis

Aortic Calcification - is it a Marker for Carotid Artery Stenosis?

Start date: February 2012
Phase: N/A
Study type: Observational

Atherosclerosis is the major contributor for the morbidity and mortality for the variety of cardiovascular diseases. Aortic calcification on x-ray is a marker for arterial atherosclerosis and an independent prognostic factor for the morbidity and mortality from a cardiovascular event. Carotid artery stenoses is the current accepted indication for interventional treatment of carotid artery, for the prevention of embolic event, while other arterial atherosclerosis indication, is for hemodynamic disturbance and ischemic outcome. This research will try to find whether incidental aortic calcification can predict carotid artery stenosis. Two groups will be chosen: group A - patients who had CT scan in the hospital (for different indications); Group B - patients (not from the first group) who have a significant carotid artery stenosis who are indicated for interventional treatment. The data to analyze: Group A - Patients with aortic calcification, carotid artery stenosis, and patients with both Group B - Patients who have aortic calcification Comparison of the populations within the group and among the two will show if a significant correlation between aortic calcification and carotid artery stenosis exist.

NCT ID: NCT01158066 Not yet recruiting - Clinical trials for Coronary Artery Calcification

Association Between Non-alcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Calcification

Start date: August 2011
Phase: N/A
Study type: Interventional

Coronary artery disease are 8 times more prevalent in patients with NAFLD then the general population and are being considered the most common cause of death. Cardiac CT is a reliable non invasive method in demonstrating Coronary Plaques. However the association between coronary artery calcium score (CAC) and NAFLD remains controversial